Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies.
This information is produced for use by NHS healthcare professionals.
This report looks at prescribing trends in primary care for antibacterial drugs at SICBL and ICB level with particular focus on prescribing volume of antibacterial agents such as cephalosporins, quinolones, macrolides and tetracyclines. Prescribing data is weighted with STAR-PU prescribing measures, and incorporates C. difficile rates and non-medical prescribing.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Quarterly
July 2020 to June 2023
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in September 2023.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
The purpose of this bulletin is to present the predicted cost impact of drug price changes, both through the Price Concessions list and also monthly drug tariff (DT) cost variations. The data is calculated by matching the ePACT2 prescribing data for the latest month available to the current prices listed in the NHSBSA Drug Tariff PartVIIIA. An adjustment is also made if necessary to the prescribing data of each drug to account for any difference in dispensing days between the 2 months. Data is presented at region, ICB and SICBL level.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Monthly
October 2023 (Drug Tariff), August 2023 (ePACT2 prescribing data)
Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.
If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net
This month’s edition focuses on our Medicine Value bulletins, the environmental impact of inhaler disposal, and the recent National Patient Safety Alert on the shortage of ADHD medications. It also includes another in the series of “Meet the Team” where you can get to know the people behind the work we do. There is also information on serious shortage protocols, some key medicines availability issues, UK product launches, and the RDTC attendance at the forthcoming Clinical Pharmacy Congress (CPC) in November.
View the preview below on desktop, or click here to download a copy.
Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System leaders. The aim of this report is to determine current prescribing patterns and prescribing costs of antidiabetic treatments across the ICBs in the North of England with a particular emphasis on SGLT-2 inhibitors and GLP-1 mimetics. This will enable organisations to audit current practices against updated NICE guideline recommendations, and to estimate the financial and resource implications of prescribing SGLT-2s to a wider population.
A forthcoming addendum to this publication will estimate the gap between current prescribing of SGLT-2 inhibitors and the number of people with type 2 diabetes who are estimated to be eligible for treatment. Three versions of this addendum will be published covering the North East and Cumbria, Greater Manchester, and Yorkshire and the Humber regions.
The purpose of this bulletin is to highlight the increase in cost of paracetamol 250mg/5ml oral suspensions since May 2022. It considers the potential savings that could be achieved through cost-effective paracetamol suspension prescribing across the ICSs in the North East & Yorkshire region and Greater Manchester.
The purpose of this bulletin is to promote cost effective prescribing by highlighting the lack of evidence on the efficacy of emollient bath and shower preparations for the management of atopic eczema, in line with updated NICE guidance. It considers the potential savings that could be achieved with reduced prescribing of these products across the ICSs in the North East & Yorkshire region and Greater Manchester.
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in August 2023.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies.
This information is produced for use by NHS healthcare professionals.